Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy

Scientific Reports
Fan QiuZi-Chun Hua

Abstract

The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising cancer therapeutic agent, which kills cancer cells selectively, while leaving normal cells unharmed. However, the emerging resistance of tumor cells and patients to TRAIL-induced apoptosis limits its further application. In this study, we developed a chimeric protein Annexin V-TRAIL (designated as TP8) with higher efficacy than TRAIL both in vitro and in vivo. In vitro, the EC50 of TP8 on a series of tumor cells was much lower than wild-type TRAIL. Annexin V provided this recombinant protein with higher efficacy, while leaving tumor specificity of TRAIL unchanged since TP8 had no effects on normal cells. In vivo, TP8 effectively suppressed tumor growth and prolonged tumor doubling time and tumor growth delay time in mouse xenografts involving multiple cancer cell types including A549, Colo205 and Bel7402. This study provides a new rational strategy to treat TRAIL-resistant cancers.

References

Sep 1, 1991·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·I GiambancoR Donato
Jan 1, 1990·Journal of Neurochemistry·J A WoolgarJ H Walker
May 31, 1996·The Journal of Biological Chemistry·R M PittiA Ashkenazi
Apr 4, 1997·Science·G PanV M Dixit
Oct 6, 1997·The EMBO Journal·H WalczakC T Rauch
Aug 28, 1998·Science·A Ashkenazi, V M Dixit
Nov 5, 1998·International Journal of Clinical & Laboratory Research·M Muzio
Jul 20, 1999·The Journal of Clinical Investigation·A AshkenaziR H Schwall
Apr 27, 2000·Nature Cell Biology·J L BodmerJ Tschopp
Apr 3, 2001·Nature Medicine·D LawrenceA Ashkenazi
Sep 8, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·T S Griffith, E L Broghammer
Nov 20, 2001·Molecular and Cellular Biology·A KruegerS Kirchhoff
Jan 5, 2002·Neoplasia : an International Journal for Oncology Research·R K Srivastava
Jan 28, 2004·Nature Immunology·Jagan R Muppidi, Richard M Siegel
Nov 20, 2004·Cancer Gene Therapy·Lidong Zhang, Bingliang Fang
Apr 17, 2008·Molecular Cancer Therapeutics·Lin CaoZi-Chun Hua
Feb 24, 2009·Proceedings of the National Academy of Sciences of the United States of America·Khalid Al-NedawiJanusz Rak
Sep 25, 2009·Nature Reviews. Cancer·Daniel MenendezMichael A Resnick

❮ Previous
Next ❯

Citations

Dec 20, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Jie WangZichun Hua
Dec 12, 2018·Bioscience Reports·Xuebo XuZi-Chun Hua
Jan 10, 2017·Journal of Peptide Science : an Official Publication of the European Peptide Society·Dominik Wilms, Jörg Andrä
Oct 25, 2017·Antibodies·Agathe Dubuisson, Olivier Micheau
Dec 22, 2019·International Journal of Cancer. Journal International Du Cancer·Piotr RozgaAnna Grochot-Przeczek

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts
xenograft
PCR
Protein Assay

Software Mentioned

CELLQuest

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis